At a glance
Read the record in context
The cagrilintide record describes an amylin analog even though the navigation groups it with metabolic compounds. Its seven-day model and 5 mg catalog package should be read under that identity. Category membership alone does not convert it into a GLP-1 receptor agonist.[1]
What the research says
The cited phase 1b publication studied cagrilintide together with subcutaneous semaglutide in adults with overweight or obesity. Ninety-five participants received treatment. The controlled, ascending-dose design examined the combination over 20 weeks, including a period of escalation followed by exposure at the assigned study level.[2]
Researchers measured adverse events, plasma exposure, peak concentration, half-life, and exploratory changes in body weight and glycemic measures. Cagrilintide half-life ranged from 159 to 195 hours, with median peak times between 24 and 72 hours. The library's long-duration model draws on this clinical pharmacokinetic context.[2][1]
Because semaglutide was part of the study regimen, the reported body-weight findings are combination results. They do not isolate every effect of cagrilintide alone. The paper also distinguishes its pharmacokinetic measurements from exploratory metabolic outcomes, a useful boundary when interpreting a long-acting amylin analog.[2]
Cited amounts
The library records 5 mg as a supplier catalog package amount. This is the total listed in that presentation, not an amount selected for administration. No personal dosing range is inferred from it.[1][3]
Explore the Cagrilintide dosing chartHalf-life and timing
At 168 hours per half-life, the illustrated amount reaches 25% after two weeks and 6.25% after four weeks. The fifth interval ends at 840 hours, or five weeks, with 3.125% remaining. These landmarks show how a long-acting model distributes its time axis. They do not establish the duration of an individual response or describe a combination containing another molecule. The research context belongs to cagrilintide, and this single-compound equation cannot infer separate inputs for an unspecified combination.[1][5]
Explore the Cagrilintide half-life modelReconstitution
Take the catalog's 5 mg only as a known mass for a hypothetical liquid example. With a final volume of 2 mL the quotient is 2.5 mg/mL; a 0.1 mL portion would represent 0.25 mg. Doubling the assumed volume would halve that portion's represented mass. This relationship explains a calculator's behavior without selecting any of those values clinically. The supplier's package listing does not establish a preparation method, a combination ratio, or an administration sequence for the investigational molecule.[3]
Tracking it in PinPoint
From a reference to a record
Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Enter vial size in mg, mcg, or IU and water volume for instant concentration and syringe units. Track vials and prefilled pens side by side.[4]
The Home curve models your levels between doses from published half-life data. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.
Get PinPoint on the App StoreFrequently asked questions
- Does a cagrilintide guide describe a GLP-1 molecule?
- The compound description identifies a long-acting amylin analog. Its position in the library's metabolic category is a navigation choice. The stored timing estimate and package example belong to cagrilintide itself, not to an assumed combination product.[1][2]
- Does the cagrilintide calculator establish a combination ratio?
- No additional molecule appears in this entry's package or conversion example. A 5 mg cagrilintide listing is not the composition of an unspecified combined product. A combination would need its own independently known quantities and source context.[1][5]
- Why can cagrilintide and semaglutide share a displayed time interval?
- The library happens to store 168 hours for both records. The same number generates the same fractional time scale, but the compound descriptions identify different molecules. Equal model intervals do not imply equal pharmacology, concentrations, or administration amounts.[1][5]
- Can a peptide tracker app record Cagrilintide?
- PinPoint's compound library includes Cagrilintide. The app description covers logging compound, dose, site, and pain level, as well as viewing modeled levels between recorded doses. The curve uses published reference inputs and does not account for individual variation. The tracker records the schedule entered by its user; it does not choose a dose or recommend a schedule change.[1][4]
Sources
Facts and reference links were retrieved from the PinPoint application library on 5 October 2026. Links below preserve the library's citations; a catalog source supports a package amount only. Source references carried from the library have not all been independently reverified. Arithmetic examples are identified separately from clinical evidence.
- PinPoint compound library, CagrilintideSnapshot of the application library; its references and uncertainty are retained below.Retrieved 2026-10-05 · library
- PubMed pharmacology reference 33894838Identity and research summary checked against this document on 5 October 2026. PubMed abstract, retrieved through NCBI EFetch.Retrieved 2026-10-05 · library-reference
- Supplier catalog package referencePackage amount only; not a clinical amount or endorsement.Retrieved 2026-10-05 · supplier
- PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
- Unit conversion and exponential-decay arithmeticC = amount / volume; remaining fraction = 2^(-elapsed / half-life). These are illustrations, not measurements.Retrieved 2026-10-05 · arithmetic